Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Scheithauer, W; Prager, G; Greil, R; Mlineritsch, B; Schaberl-Moser, R; Gerger, A; Langle, F; Viragos-Toth, I; Andel, J; Pichler, A; Pecherstorfer, M; Kretschmer, A; Seebacher, A; Jagdt, B; Eisterer, W; Krippl, P.
Secondary resectability rates observed in a multicenter randomized phase II study of modified capecitabine/ irinotecan (mXELIRI) plus bevacizumab (bev) followed by capecitabine/oxaliplatin (XELOX) plus bev or the reverse sequence in patients with metastatic colorectal cancer (mCRC)
ANN ONCOL. 2016; 27: -41st Congress of the European-Society-for-Medical-Oncology (ESMO); OCT 07-11, 2016; Copenhagen, DENMARK.
Doi: 10.1093/annonc/mdw370.41
[Poster]
Web of Science
FullText
FullText_MUG
- Autor*innen der Med Uni Graz:
- Gerger Armin
- Krippl Peter
- Schaberl-Moser Renate
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):